Cover Image
市場調查報告書

視神經脊髓炎 (戴維克症候群):開發中產品分析

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 293889
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
視神經脊髓炎 (戴維克症候群):開發中產品分析 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 92 Pages
簡介

以戴維克症候群知名的視神經脊髓炎 (NMO) 是腦,脊髓,神經由於疾病或受傷所引起的罕見神經病變,或是自體免疫系統異常反應,攻擊了體內細胞和組織的自體免疫疾病。也有免疫系統攻擊髓鞘的病例。症狀有失明,四肢無力感,麻痺,腸及膀胱問題等。

本報告涵括全球視神經脊髓炎治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

簡介

  • 調查範圍

視神經脊髓炎 (戴維克症候群)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中的治療藥:各企業
  • 開發中的治療藥:各大學·研究機關
  • 開發中的產品:各企業
  • 開發中的產品:各大學·研究機關

視神經脊髓炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

視神經脊髓炎:開發治療藥的企業

  • 2-BBB Medicines BV
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals Inc
  • Biogen Inc
  • Bionure Farma SL
  • 中外製藥
  • Clene Nanomedicine Inc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • LFB SA
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Opexa Therapeutics Inc
  • Shire Plc

藥物簡介

視神經脊髓炎:暫停中的計劃

視神經脊髓炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9707IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 5 and 7 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuromyelitis Optica (Devic's Syndrome) - Overview
    • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • Alexion Pharmaceuticals Inc
    • Apellis Pharmaceuticals Inc
    • Arrien Pharmaceuticals LLC
    • Biogen Inc
    • Bionure Farma SL
    • Chugai Pharmaceutical Co Ltd
    • HanAll Biopharma Co Ltd
    • LFB SA
    • MedImmune LLC
    • Opexa Therapeutics Inc
    • Shire Plc
    • Vicore Pharma AB
  • Neuromyelitis Optica (Devic's Syndrome) - Drug Profiles
    • 2B-3201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANV-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARN-6039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNMAU-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-15107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPX-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • satralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-623 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ublituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
  • Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
      • Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
      • Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
      • Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
      • Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
      • Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
      • May 08, 2015: Initiation Of Phase I Clinical Program
      • Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
      • Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
      • Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
      • Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
      • Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
      • Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
      • Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
      • Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by 2-BBB Medicines BV, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma SL, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB SA, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune LLC, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics Inc, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Vicore Pharma AB, H2 2017
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top